Biology Reference
In-Depth Information
170. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in
familial pancreatic carcinoma.
190. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of
head and neck squamous cell carcinoma in patients with Fanconi
anemia.
Arch Otolaryngol Head Neck Surg
2003;129(1):106
e
12.
191. Verhagen CVM, Hageman F, Balm A, et al. Functional FA
pathway deficiency in HNSCC cell lines.
Proceedings of the 56th
Annual Meeting of the Radiatation Research Society, Maui, HI
; 2010:
168.
192. Ameziane N, Chen F, Leemans CR, Brakenhoff RH, Joenje H. No
evidence for FANCF gene silencing in head-and-neck squamous
cell carcinomas.
Cell Oncol
2009;31(1):53
e
6.
193. Burkitt K, Ljungman M. Compromised Fanconi anemia response
due to BRCA1 deficiency in cisplatin-sensitive head and neck
cancer cell lines.
Cancer Lett
2007;253(1):131
e
7.
194. Snyder ER, Ricker JL, Chen Z, Waes CV. Variation in cisplatinum
sensitivity is not associated with Fanconi Anemia/BRCA
pathway inactivation in head and neck squamous cell carcinoma
cell lines.
Cancer Lett
2007;245(1-2):75
e
80.
195. Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillo-
mavirus DNA and p53 polymorphisms in squamous cell carci-
nomas from Fanconi anemia patients.
J Natl Cancer Inst
2003;
95(22):1718
e
21.
196. Park JW, Pitot HC, Strati K, et al. Deficiencies in the Fanconi
anemia DNA damage response pathway increase sensitivity to
HPV-associated head and neck cancer.
Cancer Res
2010;70(23):
9959
e
68.
197. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility
to breast cancer, brain tumors, and Fanconi anemia.
J Natl Cancer
Inst
2003;95(20):1548
e
51.
198. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor
olaparib induces significant killing of ATM-deficient lymphoid
tumor cells in vitro and in vivo.
Blood
2010;116(22):4578
e
87.
199. Rosen EM, Fan S, Goldberg ID. BRCA1 and prostate cancer.
Cancer Invest
2001;19(4):396
e
412.
200. Friedenson B. BRCA1 and BRCA2 pathways and the risk of
cancers other than breast or ovarian.
MedGenMed
2005;7(2):60.
201. Wong AK, Ormonde PA, Pero R, et al. Characterization of a car-
boxy-terminal BRCA1 interacting protein.
Oncogene
1998;17(18):
2279
e
85.
202. Hiramoto T, Nakanishi T, Sumiyoshi T, et al. Mutations of a novel
human RAD54 homologue, RAD54B, in primary cancer.
Oncogene
1999;18(22):3422
e
6.
203. Matsuda M, Miyagawa K, Takahashi M, et al. Mutations in the
RAD54 recombination gene in primary cancers.
Oncogene
1999;
18(22):3427
e
30.
204. Helleday T. Homologous recombination in cancer development,
treatment and development of drug resistance.
Carcinogenesis
2010;31(6):955
e
60.
205. Thacker J. The RAD51 gene family, genetic instability and cancer.
Cancer Lett
2005;219(2):125
e
35.
206. Barker CA, Powell SN. Enhancing radiotherapy through a greater
understanding of homologous recombination.
Semin Radiat Oncol
2010;20(4):267
e
73. e3.
207. Plo I, Lopez B. AKT1 represses gene conversion induced by
different genotoxic stresses and induces supernumerary centro-
somes and aneuploidy in hamster ovary cells.
Oncogene
2009;
28(22):2231
e
7.
208. Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS. AKT1
inhibits homologous recombination by inducing cytoplasmic
retention of BRCA1 and RAD51.
Cancer Res
2008;68(22):9404
e
12.
209. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compro-
mises homologous recombination repair in astrocytes: implica-
tions for glioblastoma therapy with temozolomide or
poly(ADP-ribose) polymerase inhibitors.
Cancer Res
2010;70(13):
5457
e
64.
J Natl Cancer Inst
2003;95(3):
214
e
21.
171. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing
identifies PALB2 as a pancreatic cancer susceptibility gene.
Science
2009;324(5924):217.
172. van der Heijden MS, brody JR, Kern SE. Functional screen of the
Fanconi Anemia pathway in cancer cells by FANCD2 immuno-
blot.
Cancer Biol Ther
2004;3(6):538
e
9.
173. Van Der Heijden MS, Brody JR, Kern SE. Functional screen of the
fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
Cancer Biol Ther
2004;3(6):534
e
7.
174. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi
anemia gene mutations in young-onset pancreatic cancer.
Cancer
Res
2003;63(10):2585
e
8.
175. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene muta-
tions in patients with apparently sporadic pancreatic carcinomas.
Cancer Res
1996;56(23):5360
e
4.
176. Rogers CD, van der Heijden MS, Brune K, et al. The genetics of
FANCC and FANCG in familial pancreatic cancer.
Cancer Biol
Ther
2004;3(2):167
e
9.
177. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels
as an indicator of chemoresistance in lung cancer.
Hum Mol Genet
2004;13(20):2443
e
9.
178. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: A novel prog-
nostic factor in resected non-small-cell lung cancer.
PLoS ONE
2007;2(11). e1129.
179. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT.
Inactivation of the Fanconi anemia/BRCA pathway in lung and
oral cancers: implications for treatment and survival.
Oncogene
2004;23(4):1000
e
4.
180. Lee MN, Tseng RC, Hsu HS, et al. Epigenetic inactivation of the
chromosomal stability control genes BRCA1, BRCA2, and XRCC5
in non-small cell lung cancer.
Clin Cancer Res
2007;13(3):832
e
8.
181. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ.
ERCC1, hRad51, and BRCA1 protein expression in relation to
tumour response and survival of stage III/IV NSCLC patients
treated with chemotherapy.
Lung Cancer
2005;50(2):211
e
9.
182. Ferrer M, Span SW, Vischioni B, et al. FANCD2 expression in
advanced non-small-cell lung cancer and response to platinum-
based chemotherapy.
Clin Lung Cancer
2005;6(4):250
e
4.
183. Willers H, Kachnic LA, Birkelbach M, et al. Detection of homol-
ogous recombination defects in NSCLC.
J Thorac Oncol
2010;5(12)
(Suppl. 7): S516.
184. Miyagawa K. Clinical relevance of the homologous recombina-
tion machinery in cancer therapy.
Cancer Sci
2008;99(2):187
e
94.
185. Rahn JJ, Adair GM, Nairn RS. Multiple roles of ERCC1-XPF in
mammalian interstrand crosslink repair.
Environ Mol Mutagen
2010;51(6):567
e
81.
186. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key
pathways
in lung adenocarcinoma.
Nature
2008;455(7216):
1069
e
75.
187. Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense
mutations but not allelic variants alter the function of ATM by
dominant interference in patients with breast cancer.
Proc Natl
Acad Sci USA
2002;99(2):925
e
30.
188. Zhang J, Ma Z, Treszezamsky A, Powell SN. MDC1 interacts with
Rad51 and facilitates homologous recombination.
Nat Struct Mol
Biol
2005;12(10):902
e
9.
189. Bartkova J, Horejsi Z, Sehested M, et al. DNA damage response
mediators MDC1 and 53BP1: constitutive activation and aberrant
loss in breast and lung cancer, but not in testicular germ cell
tumours.
Oncogene
2007;26(53):7414
e
22.